What has FDA cited under ICH Q9?

1 DSRV article cite ICH Q9. Enforcement cases behind them: FDA draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, published March 2026; comment period closed May 8, 2026. Inspection exposure across them: 1 moderate.

What does DSRV recommend for ICH Q9?

From the newest article (FDA Finally Wrote Down What a Good 483 Response Requires): A credible 15-business-day response is a lagging indicator of investigation and CAPA infrastructure that must exist months before the inspection closeout, because root cause quality cannot be built inside the response window. DSRV's matching service is the Quality Risk Management Tune-up, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.

Browse by regulation1 article · 1 moderate

ICH Q9

Every DSRV article whose Regulatory Snapshot cites ICH Q9: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set

What has FDA cited under ICH Q9?: 1 DSRV article cite ICH Q9. Enforcement cases behind them: FDA draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, published March 2026; comment period closed May 8, 2026. Inspection exposure across them: 1 moderate.
What does DSRV recommend for ICH Q9?: From the newest article (FDA Finally Wrote Down What a Good 483 Response Requires): A credible 15-business-day response is a lagging indicator of investigation and CAPA infrastructure that must exist months before the inspection closeout, because root cause quality cannot be built inside the response window. DSRV's matching service is the Quality Risk Management Tune-up, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.

June 20265 min readModerate exposurecited as a tag
FDA Finally Wrote Down What a Good 483 Response Requires
For the first time, FDA has published dedicated draft guidance on what a credible CGMP 483 response must contain. The requirements are not new. The formal standard is.
Case
FDA draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, published March 2026; comment period closed May 8, 2026.
DSRV take
A credible 15-business-day response is a lagging indicator of investigation and CAPA infrastructure that must exist months before the inspection closeout, because root cause quality cannot be built inside the response window.

Address this risk

Quality Risk Management Tune-up

Bring the document that has to hold up under ICH Q9. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about ICH Q9

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.